Modality
Radioligand
MOA
GLP-1/GIP
Target
BET
Pathway
NF-κB
Wilms
Development Pipeline
Preclinical
~May 2015
→ ~Aug 2016
Phase 1
~Nov 2016
→ ~Feb 2018
Phase 2
~May 2018
→ ~Aug 2019
Phase 3
~Nov 2019
→ ~Feb 2021
NDA/BLA
May 2021
→ Jan 2030
NDA/BLACurrent
NCT07303442
40 pts·Wilms
2022-04→2030-01·Terminated
NCT08086307
592 pts·Wilms
2021-05→2026-09·Terminated
632 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-09-125mo awayPh3 Readout· Wilms
2030-01-233.8y awayPh3 Readout· Wilms
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
NDA/BLA
Termina…
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2026-09-12 · 5mo away
Wilms
Ph3 Readout
2030-01-23 · 3.8y away
Wilms
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07303442 | NDA/BLA | Wilms | Terminated | 40 | NT-proBNP |
| NCT08086307 | NDA/BLA | Wilms | Terminated | 592 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| 207-5197 | Samsung Biologics | Approved | BET |